Recently, a document on the suspension of the new crown project performance salary plan went viral on the Internet, which mentioned that the new crown vaccine of Beijing Sinovac Zhongwei Biotechnology Company has all been discontinued and the company currently has no new crown vaccine products for sale. As soon as this news was announced, it aroused widespread attention and discussion from all walks of life. Faced with this situation, we can't help but ask: why is there a phenomenon of "getting off" with the new crown vaccine? Is the new crown vaccine market really so "sluggish"? According to reports, not only Sinovac, but also in the past two years, a number of companies that have been developing new crown vaccines have either announced a turnaround, or stopped investing, or even stopped paying employee performance wages. Among them, including well-known companies such as the domestic Three Musketeers and Shanghai Pharmaceutical CanSino. It is important to note that this is not an isolated case, but a trend.
What is the reason behind this? First of all, the cost of vaccine research and development is high, but the virus mutates rapidly, and the speed of vaccine iteration cannot keep up. A vaccine industry practitioner said that the developed vaccine will soon be replaced by a new virus, making it difficult for companies to afford the cost of vaccine iteration, let alone the cost of clinical trials before commercialization. Second, the public's willingness to get vaccinated has decreased significantly. This is also one of the important reasons why companies have given up on developing and producing new crown vaccines. Virologist Chang Rongshan said that if the new crown vaccine is procured, but not many people come to get vaccinated, it will lead to a backlog and waste of vaccines. At the same time, a number of new crown vaccines have been approved for use, but people's willingness to get vaccinated has decreased, which has brought huge challenges to the vaccine market.
Recently, jnThe spread of the 1 variant is rising rapidly abroad, which also brings new challenges and pressures to the vaccine market. However, for vaccine companies and R&D institutions, in the face of the dilemma of the new crown vaccine market, how to adjust their strategies and improve the competitiveness of the vaccine market is a difficult problem in front of them. Therefore, we have reason to believe that more research and efforts will be invested in vaccine research and development and marketing in the future to better meet the society's demand for vaccines. To sum up, the emergence of the phenomenon of "getting off" of the new crown vaccine is not caused by a single reason, but the result of a combination of factors.
In the face of the dilemma of the vaccine market, we hope that relevant departments and enterprises can work together to find better solutions to ensure the stability and healthy development of the vaccine market.